Roche’s Phase III trial of fenebrutinib in RMS meets primary endpoint

​Roche has reported that the pivotal Phase III FENhance 1 trial of its investigational BTK inhibitor, fenebrutinib, in RMS, achieved the primary endpoint.

The post Roche’s Phase III trial of fenebrutinib in RMS meets primary endpoint appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.